cyclopentolate and phenylephrine

Action and Spectrum

Actions and spectrum: 

cyclopentolate is a type of medication known as an anticholinergic, which works by blocking the action of acetylcholine, a chemical that transmits nerve impulses. Specifically, cyclopentolate inhibits the action of acetylcholine at the muscarinic receptors in the iris sphincter and ciliary muscle of the eye, leading to pupil dilation and paralysis of the ciliary muscle.

This allows the eye to be examined more easily and is often used in eye exams or before eye surgery. Phenylephrine, on the other hand, is a sympathomimetic medication that works by stimulating the sympathetic nervous system. It acts on the alpha-adrenergic receptors in the dilator muscle of the iris, causing it to contract and leading to dilation of the pupil.

Phenylephrine is often combined with cyclopentolate to enhance the dilation of the pupil and maintain the dilation for a longer period of time. Together, cyclopentolate and phenylephrine are used in ophthalmology for a variety of procedures, including eye exams, retinal imaging, and some types of eye surgery. They are also used to treat certain eye conditions, such as iritis and uveitis, by reducing inflammation and pain. 

Drug Interaction

Adverse Reaction

Frequency not defined 

Blurred vision 

Hypersensitivity reactions like dermatitis or allergic conjunctivitis 

Headache 

Transient burning 

Burning sensation in eye 

Sensitivity to light 

Reactive hyperemia 

Transient keratitis  

Rare 

• Hypertension, palpitation, tachyarrhythmia, tachycardia, vasodilatation 
• confusion, psychotic disorder, seizure, tremors, Ataxia, occipital headache, raised intraocular pressure. 
• Pallor or blanching 
• Increased perspiration 

Black Box Warning

Black Box Warning:  

There are no black box warnings associated with cyclopentolate and Phenylephrine. 

Contraindication / Caution

Contraindication/Caution: 

Contraindication: 

cyclopentolate and phenylephrine eye drops are contraindicated in patients with hypersensitivity reactions to either drug or to any component of the formulation. They are also contraindicated in patients with narrow-angle glaucoma. Additionally, caution should be taken when administering these eye drops to patients with a history of cardiovascular disease, hypertension, or hyperthyroidism.  

Caution: 

• Cardiovascular disease: Phenylephrine can cause an increase in blood pressure and heart rate, so caution should be taken in patients with cardiovascular disease. 
• Liver and kidney disease: These drugs may be excreted through the liver and kidneys, so patients with liver or kidney disease should be monitored carefully. 
• Thyroid disease: Phenylephrine can stimulate the thyroid gland, so patients with thyroid disease should be monitored closely. 
• Diabetes: Phenylephrine can affect blood sugar levels, so patients with diabetes should be monitored closely. 
• Closed-angle glaucoma: cyclopentolate should be used with caution in patients with closed-angle glaucoma, as it can cause an increase in intraocular pressure. 
• Elderly patients: Elderly patients may be more sensitive to the effects of these drugs and may require lower doses. 
• Children: cyclopentolate and phenylephrine are generally considered safe for use in children, but doses should be adjusted based on the child’s weight and age.

Comorbidities: 

cyclopentolate and phenylephrine are ophthalmic drugs used for the dilation of the pupil during eye examinations. As such, there are not many specific comorbidities related to their use. However, caution should be exercised in patients with a history of narrow-angle glaucoma or those at risk for developing it, as pupil dilation can cause an acute angle-closure glaucoma attack in susceptible individuals. 

Pregnancy / Lactation

Pregnancy consideration: pregnancy category C 

Lactation: safety and efficacy not established  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women. 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women. 
• Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology: 

cyclopentolate is a muscarinic receptor antagonist that works by blocking the effects of acetylcholine at the muscarinic receptors in the ciliary body and the iris sphincter muscle. This causes dilation of the pupil (mydriasis) and paralysis of the ciliary muscle (cycloplegia), leading to relaxation of the lens and decreased ability to accommodate near vision. 

Phenylephrine is an alpha-adrenergic agonist that works by stimulating the alpha receptors in the dilator muscle of the iris, leading to contraction and dilation of the pupil (mydriasis). It also acts on the blood vessels of the eye, causing vasoconstriction and reducing intraocular pressure. When these two drugs are used together, they can provide more effective dilation of the pupil for ophthalmic procedures. The cycloplegic effect of cyclopentolate can also help with the examination of the fundus (back of the eye).  

Pharmacodynamics: 

• cyclopentolate: It is an antimuscarinic drug that blocks muscarinic receptors in the eye, leading to pupil dilation (mydriasis) and paralysis of the ciliary muscle, which allows for easier examination of the eye. It has a rapid onset of action, typically within 15-30 minutes after administration, and the effects can last for several hours. 
• Phenylephrine: It is a sympathomimetic drug that acts as an alpha-1 adrenergic receptor agonist. It causes vasoconstriction of blood vessels in the eye, leading to pupil dilation (mydriasis) and an increase in intraocular pressure. Phenylephrine has a rapid onset of action, typically within 5-10 minutes after administration, and the effects can last for several hours. 
• When used in combination, cyclopentolate and phenylephrine can provide greater mydriasis and cycloplegia for ophthalmic procedures.

Pharmacokinetics: 

Absorption 

cyclopentolate and phenylephrine are typically administered as ophthalmic solutions, which are applied directly to the eye. After application, the drugs are absorbed through the cornea and reach the anterior chamber of the eye. The onset of action is relatively rapid, with maximal effects occurring within 30 minutes to an hour after administration. 

Distribution 

cyclopentolate and phenylephrine are administered locally and topically to the eye and have a limited distribution. cyclopentolate is primarily distributed to the anterior segment of the eye and the aqueous humor, with minimal systemic absorption. Phenylephrine has a local vasoconstrictive effect, but systemic absorption can occur and may cause systemic side effects. 

Metabolism 

cyclopentolate and phenylephrine are not metabolized in the body. Instead, they are eliminated through renal excretion or metabolic breakdown in the liver. cyclopentolate is hydrolyzed in the liver and excreted in the urine, while phenylephrine is largely metabolized by monoamine oxidase (MAO) enzymes in the liver and excreted in the urine. The elimination half-life of cyclopentolate is approximately 2 hours, while the half-life of phenylephrine is around 2-3 hours. 

Elimination and excretion 

cyclopentolate and phenylephrine are primarily eliminated through renal excretion. The exact metabolism and elimination pathways for these drugs are not well-defined in the literature. However, studies suggest that cyclopentolate undergoes hepatic metabolism and subsequent urinary excretion, while phenylephrine is primarily excreted unchanged in the urine. The half-life of cyclopentolate is around 3 hours, and the half-life of phenylephrine is around 2.1 to 2.5 hours. 

Adminstartion

Administration: 

cyclopentolate and phenylephrine are usually administered as eye drops. The typical dosage of cyclopentolate is one or two drops in the affected eye(s), while the dosage of Phenylephrine is one drop in the affected eye(s).

The frequency of administration and the duration of treatment may vary depending on the condition being treated and the patient’s response to the medication. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: cyclopentolate and phenylephrine 

Pronounced: [ SYE-kloe-PEN-toe-late-and-FEN-il-EFF-rin-off-THAL-mik ]  

Why do we use cyclopentolate and phenylephrine? 

• cyclopentolate and phenylephrine are often used in combination as eye drops for ophthalmic procedures, such as eye examinations, refraction tests, and funduscopy. 
• cyclopentolate is a mydriatic agent that causes dilation of the pupil, which allows for better visualization of the structures inside the eye during these procedures. It works by blocking the muscarinic receptors in the iris sphincter muscle, preventing the muscle from contracting and causing the pupil to dilate. 
• Phenylephrine is a sympathomimetic agent that causes vasoconstriction of the blood vessels in the eye, reducing redness and inflammation. It also helps to dilate the pupil further. 
• Together, these drugs help to create a clear view of the inside of the eye for the physician or ophthalmologist performing the procedure.